The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2017

Filed:

May. 22, 2014
Applicants:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Glaxosmithkline Intellectual Property (No.2) Limited, Brentford, Middlesex, GB;

Inventors:

David Bellovin, South San Francisco, CA (US);

Kevin Baker, Burlingame, CA (US);

Thomas Brennan, Saratoga, CA (US);

Arundathy Nirmalini Pandite, Research Triangle Park, NC (US);

Bijoyesh Mookerjee, Collegeville, PA (US);

Maurice P. DeYoung, Collegeville, PA (US);

Rakesh Kumar, Collegeville, PA (US);

Assignees:

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

GlaxoSmithKline Intellectual Property (No.2) Limited, Brentford, Middlesex, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 31/337 (2006.01); C07K 14/71 (2006.01); C12Q 1/68 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 33/24 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/179 (2013.01); A61K 31/337 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); C07K 14/71 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); G01N 33/57496 (2013.01); C07K 2319/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/49 (2013.01); G01N 2333/50 (2013.01); G01N 2333/503 (2013.01); G01N 2333/515 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.


Find Patent Forward Citations

Loading…